OncoMatch/Clinical Trials/NCT06801041

TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

Is NCT06801041 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Psilocybin for depression.

Phase 2RecruitingM.D. Anderson Cancer CenterNCT06801041Data as of May 2026

Treatment: Psilocybin — This clinical research study is to learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy for cancer survivors with depression and/or anxiety.

Check if I qualify

Extracted eligibility criteria

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

The University of Texas M. D. Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify